Spironolactone vs Amiloride for Resistant Hypertension A Randomized Clinical Trial
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- Nature IndexSCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION333(23) · pp.2073 · 2025
- 피인용
- Web of Science 34Scopus 30
- FWCI (Scopus)
- 10.05
- JCR IF
- JCR 2024 55
- ISSN
- 0098-7484
저자
- Lee, Chan Joo제1저자Yonsei Univ, Coll Med, Severance Cardiovasc Hosp, Div Cardiol, 50-1 Yonsei Ro, Seoul 03722, South Korea
- Ihm, Sang-HyunCatholic Univ Korea, Bucheon St Marys Hosp, Dept Internal Med, Div Cardiol, Seoul, South Korea
- Shin, Dong-HoSeverance Hosp, Dept Internal Med, Div Gen Internal Med, Seoul, South Korea
- Jeong, Jin-OkChungnam Natl Univ, Chungnam Natl Univ Hosp, Coll Med, Dept Cardiol Internal Med, Daejeon, South Korea
- Kim, Ju HanChonnam Natl Univ Hosp, Dept Cardiol, Gwangju, South Korea
- Chun, Kyeong-HyeonNatl Hlth Insurance Serv Ilsan Hosp, Div Cardiol, Goyang, South Korea
- Ryu, JiWungDankook Univ Hosp, Dept Internal Med, Div Cardiol, Cheonan, South Korea
- Lee, Hae-YoungSeoul Natl Univ Hosp, Dept Internal Med, Seoul 03080, South Korea
- Choi, SeonghoonHallym Univ, Kangnam Sacred Heart Hosp, Coll Med, Div Cardiol,Dept Internal Med, Seoul, South Korea
- Lee, Eun MiWonkwang Univ, Sanbon Hosp, Dept Internal Med, Div Cardiol, Gunpo, South Korea
- 최정현Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Div Cardiol,Dept Internal Med, Busan, South Korea
- Kim, Kwang-IlSeoul Natl Univ, Bundang Hosp, Coll Med, Dept Internal Med, Seongnam, South Korea
- Shin, JinhoHanyang Univ, Coll Med, Dept Internal Med, Div Cardiol, Seoul, South Korea
- Pyun, Wook BumEwha Womans Univ, Seoul Hosp, Coll Med, Div Cardiol,Dept Internal Med, Seoul, South Korea
- Kim, Dae-Hee교신저자Univ Ulsan, Coll Med, Asan Med Ctr, Div Cardiol,Dept Internal Med, 88 Olympic Ro,43 GIL, Seoul 05505, South Korea
- Park, Sungha교신저자Yonsei Univ, Coll Med, Severance Cardiovasc Hosp, Div Cardiol, 50-1 Yonsei Ro, Seoul 03722, South Korea
- Williams, BryanUCL, Inst Cardiovasc Sci, London, England
초록
Importance Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomized clinical trials have compared the efficacy of spironolactone and amiloride in patients with resistant hypertension. Objective To determine whether amiloride is noninferior to spironolactone in reducing home-measured systolic blood pressure (SBP) in patients with resistant hypertension. Design, Setting, and Participants Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled. Intervention Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively. Main Outcomes and Measures The primary end point was the between-group difference in home SBP change at week 12, with a noninferiority margin of -4.4 mm Hg for the lower bound of the confidence interval. Secondary end points included achievement rates of home- and office-measured SBP of less than 130 mm Hg. Results The median age of the study population was 55 years, with 70% male. There were no differences between groups in demographic characteristics other than use of alpha-blockers (8.6% in the amiloride group and 0% in the spironolactone group). The mean baseline home SBPs were 141.5 (SD, 7.9) mm Hg and 142.3 (SD, 8.5) mm Hg in the amiloride and spironolactone groups, respectively. At week 12, mean home SBP measurements were changed from baseline by -13.6 (SD, 8.6) mm Hg and -14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, -0.68 mm Hg; 90% CI, -3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone. Home-measured achievement rates of SBP less than 130 mm Hg in the amiloride and spironolactone groups were 66.1% and 55.2%, respectively, and office-measured achievement rates of SBP less than 130 mm Hg were 57.1% and 60.3%, respectively, with no difference between the 2 groups. One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group. Conclusions and Relevance Amiloride was noninferior to spironolactone in lowering home SBP, suggesting that it could be an effective alternative for treatment of resistant hypertension.
키워드
식별자
- Scopus EID
- 2-s2.0-105009270116
- WoS UID
- 001489621500001



로그인
연구물 목록으로